CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $29.4M, lower than 95% of all stocks globally
- PositionCurrent ratio is 26.4×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.53%
Annual Rate
CNY 0.52Paid semi-annual
Payout Ratio
69.6%Moderate
Payback Period
89.5 yr
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
3.68BCNY547.66M · vs all stocks (USD)
Trailing P/E
77.11xvs Biotechnology peers
Revenue (TTM)
197.68MCNY29.40M · vs all stocks (USD)
Profit Margin
24.58%vs Biotechnology peers
Beta
0.5780xvs all stocks
52-Week Change
34.76%vs all stocks
Forward Annual Dividend Yield
1.53%vs all stocks
Market Capitalization
3.68BCNY547.66M · vs all stocks (USD)
Enterprise Value
2.82BCNY419.05M · vs all stocks (USD)
Trailing P/E
77.11xvs Biotechnology peers
Price to Sales (TTM)
19.42xvs Biotechnology peers
Price to Book (MRQ)
3.45xvs Biotechnology peers
Enterprise to Revenue
14.26xvs Biotechnology peers
Enterprise to EBITDA
41.45xvs Biotechnology peers
Gross Margin
72.65%vs Biotechnology peers
Profit Margin
24.58%vs Biotechnology peers
Return on Assets (TTM)
2.73%vs Biotechnology peers
Return on Equity (TTM)
4.39%vs Biotechnology peers
Revenue (TTM)
197.68MCNY29.40M · vs all stocks (USD)
Revenue per Share (TTM)
2.18CNYUpdated Aug 21, 2026Quarterly Revenue Growth
5.70%vs Biotechnology peers
Gross Profit (TTM)
151.72MCNY22.56M · vs all stocks (USD)
EBITDA (TTM)
84.54MCNY12.57M · vs all stocks (USD)
Net Income (TTM)
48.60MCNY7.23M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-84.90%vs Biotechnology peers
Operating Cash Flow (TTM)
69.70MCNY10.36M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-21.22MCNY-3.16M · vs all stocks (USD)
Forward Annual Dividend Rate
0.5200CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
1.53%vs all stocks
Trailing Annual Dividend Rate
0.3800CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.12%vs all stocks
Payout Ratio
69.57%vs Biotechnology peers
Revenue
196.21MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
42.93MCNYFY2025 · Dec 31, 2025Gross Profit
153.28MCNYFY2025 · Dec 31, 2025Operating Income
54.86MCNY8.16M · vs all stocks (USD)
Pre-tax Income
64.21MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.42MCNYFY2025 · Dec 31, 2025Net Income
51.79MCNYFY2025 · Dec 31, 2025EBIT
64.39MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
84.54MCNYFY2025 · Dec 31, 2025Research & Development
19.51MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
36.31MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.61MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
179.66KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
107.89MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
107.89MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
51.79MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
43.45MCNYFY2025 · Dec 31, 2025Free Cash Flow
-16.03MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
33.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
51.79MCNYFY2025 · Dec 31, 2025Other Non-cash Items
496.68KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.49MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-348.08KCNYFY2025 · Dec 31, 2025Capital Expenditures
-59.48MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.43BCNYFY2025 · Dec 31, 2025Sale of Investments
2.32BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-174.09MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-34.63MCNYFY2025 · Dec 31, 2025Other Financing Charges
-692.68KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-35.32MCNYFY2025 · Dec 31, 2025Shares Outstanding
108.22MSharesUpdated Aug 21, 2026Float Shares
43.99MSharesUpdated Aug 21, 2026% Held by Insiders
68.72%vs all stocks
% Held by Institutions
1.32%vs all stocks
Total Cash (MRQ)
764.79MCNY113.73M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.07CNYUpdated Aug 21, 2026Total Debt (MRQ)
4.94MCNY735.23K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0044xvs Biotechnology peers
Current Ratio (MRQ)
26.39xvs Biotechnology peers
Book Value per Share (MRQ)
10.29CNYUpdated Aug 21, 2026Total Assets
1.16BCNY172.09M · vs all stocks (USD)
Total Current Assets
912.16MCNYFY2025 · Dec 31, 2025Total Liabilities
44.55MCNYFY2025 · Dec 31, 2025Total Non-current Assets
245.05MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
7.65MCNYFY2025 · Dec 31, 2025Total Current Liabilities
36.91MCNYFY2025 · Dec 31, 2025Cash
33.28MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.50KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
33.28MCNYFY2025 · Dec 31, 2025Other Short-term Investments
764.91MCNYFY2025 · Dec 31, 2025Accounts Receivable
36.06MCNYFY2025 · Dec 31, 2025Inventory
43.03MCNYFY2025 · Dec 31, 2025Accounts Payable
16.49MCNYFY2025 · Dec 31, 2025Short-term Debt
767.63KCNYFY2025 · Dec 31, 2025Other Current Liabilities
94.05KCNYFY2025 · Dec 31, 2025Long-term Debt
4.33MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.04MCNYFY2025 · Dec 31, 2025Common Stock (Book)
108.22MCNYFY2025 · Dec 31, 2025Retained Earnings
71.72MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.11BCNY165.46M · vs all stocks (USD)
52-Week Low
21.20CNYUpdated Aug 21, 202652-Week High
52.88CNYUpdated Aug 21, 202652-Week Change
34.76%vs all stocks
Beta
0.5780xvs all stocks
50-Day MA
37.73CNYUpdated Aug 21, 2026200-Day MA
30.31CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.27MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.66MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.4600CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 26.4×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 26.39Industry median: 5.64Industry P95: 23.02Peers compared: 261
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 19.42Revenue Growth YoY: 0.06
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $29.4M, lower than 95% of all stocks globallySignificant
Revenue (USD): 29,396,719.174Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
NeuroPace Inc.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
TaiMed Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shenzhen Yanmade Technology Co., Ltd.
2 interpretationsCash Backing With Revenue And Income StreaksLow-Leverage Liquidity Configuration
Airtac International Group
3 interpretationsCash Backing With Revenue And Income StreaksIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration
United States Lime & Minerals Inc.
3 interpretationsCash Backing With Revenue And Income StreaksIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration